Articles: function.
-
Acta Anaesthesiol Scand · Mar 2014
Review Meta AnalysisDrug-induced long QT syndrome and fatal arrhythmias in the intensive care unit.
Long QT syndrome (LQTS) is a genetic or acquired condition characterised by a prolonged QT interval on the surface electrocardiogram (ECG) and is associated with a high risk of sudden cardiac death because of polymorph ventricular tachyarrhythmia called Torsade de Pointes arrhythmia. Drug-induced LQTS can occur as a side effect of commonly used cardiac and non-cardiac drugs in predisposed patients, often with baseline QT prolongation lengthened by medication and/or electrolyte disturbances. Hospitalised patients often have several risk factors for proarrhythmic response, such as advanced age and structural heart disease. ⋯ Overdrive cardiac pacing is highly effective in preventing recurrences, and antiarrhythmic drugs should be avoided. Recent data suggest that QT prolongation is quite common in ICU patients and adversely affects patient mortality. Thus, high-risk patients should be sufficiently monitored, and the use of medications known to cause drug-induced LQTS might have to be restricted.
-
DVT/PE/Pulmonary HypertensionSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 12:15 PM - 01:15 PMPURPOSE: The long-term effect of riociguat was compared in patients with CTEPH in FC I/II versus FC III/IV at CHEST-1 baseline. ⋯ Andrea M D'Armini: Other Andrea D'Armini received fees for participation in review activities from Bayer: Hossein-Ardeschir Ghofrani: Grant monies (from industry related sources) Hossein-Ardeschir Ghofrani has received grant money paid to his institution by Bayer HealthCare: Friedrich Grimminger: Grant monies (from industry related sources) Friedrich Grimminger has received grant money paid to his institution by Bayer HealthCare: Marius M Hoeper: Consultant fee, speaker bureau, advisory committee, etc. Marius M. Hoeper has received consulting fees, honorarium and/or support for travel from Bayer: Pavel Jansa: Consultant fee, speaker bureau, advisory committee, etc. Pavel Jansa has received consulting fees, honorarium and/or support for travel to meetings from Bayer: Nick H Kim: Consultant fee, speaker bureau, advisory committee, etc. Nick H. Kim has received consulting fees, honorarium and/or support for travel to meetings from Bayer: Gerald Simonneau: Grant monies (from industry related sources) Gerald Simonneau has received grant money paid to his institution from Bayer: Adam Torbicki: University grant monies Adam Torbicki has received university grant monies for statute activities of the university: Martin Wilkins: Consultant fee, speaker bureau, advisory committee, etc. Martin Wilkins has received consulting fees, honorarium and/or support for travel to meetings from Bayer HealthCare: Arno Fritsch: Employee Arno Fritsch is a full-time employee of Bayer HealthCare: Neil Davie: Employee Neil Davie is a full-time employee of Bayer HealthCare: Eckhard Mayer: Consultant fee, speaker bureau, advisory committee, etc. Eckhard Mayer has received consulting fees, honorarium and/or support for travel to meetings from Bayer The following authors have nothing to disclose: Chen WangNo Product/Research Disclosure Information.
-
Cardiovascular Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Cardiogenic pulmonary edema occurring unilaterally is rare and presents diagnostic difficulties. ⋯ UCPE is an uncommon presentation; it should be considered in patients with unilateral pulmonary infiltrates and severely impaired left ventricular function or mitral valve diseases to avoid delay in diagnosis and appropriate treatment.Reference #1: Attias D, Mansencal N. Prevalence, characteristics, and outcomes of patients presenting with cardiogenic unilateral pulmonary edema. Circulation. 2010;122:1109-1115.Reference #2: Nitzan O, Saliba WR, Goldstein LH. Unilateral pulmonary edema: a rare presentation of congestive heart failure. Am J Med Sci. 2004; 327: 362-364Reference #3: Choi HS, Choi H, Han S, et al. Pulmonary edema during pregnancy: unilateral presentation is not rare. Circ J 2002;66:623-6DISCLOSURE: The following authors have nothing to disclose: Jessica Quah, Tan Keng LeongNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). The BEACON study evaluated the efficacy and safety of QVA149 compared with the concurrent administration of indacaterol and glycopyrronium (IND+GLY). ⋯ The study demonstrated that QVA149 provides benefits of dual bronchodilation in a single inhaler device, making it a more convenient treatment option for patients with moderate-to-severe COPDDISCLOSURE: Ronald Dahl: Consultant fee, speaker bureau, advisory committee, etc.: In the past 3 years, Professor Dahl has received compensation for consulting with Boehringer-Ingelheim, Novartis, Vectura, Roche, Elevation Pharma and Norpharma; has undertaken research funded by AstraZeneca, Boehringer- Ingelheim, C hiesi, GlaxoSmithKline, Novartis, ALK-Abello and Stallergenes; has participated in educational activities sponsored by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, ALK-Abello, Novartis, Almirall. Dalal Jadayel: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
ILD Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The cryptogenic organizing pneumonia (COP) is a disease characterized by impairment of alveolar ducts and terminal bronchioles with inflammation. It was previously known as bronchiolitis obliterans organizing pneumonia (BOOP). It affects men and women with the same incidence and may be secondary to infections, drugs or be a primary manifestation. This case report presents a patient with COP whose approach dispensed, in accordance with the patient, lung biopsy for diagnosis. Only clinical data,laboratorial and image exams were used to define the conduct. ⋯ The patient improved dramatically after introduction of corticosteroid therapy, which has been decreasing gradually in posology. This case expresses an opportunity for choice by the patient, along with the physician and scientific evidence, to a personal approach for this disease.Reference #1: Vasu TS, Cavallazzi R, Hirani A, Sharma D, Weibel SB, Kane GC. Clinical and radiologic distinctions between secondary bronchiolitis obliterans organizing pneumonia and cryptogenic organizing pneumonia. Respir Care. 2009.Reference #2: Oymak FS, Demirbas HM, Mavili E, et al. Bronchiolitis obliterans organizing pneumonia. Clinical and roentgenological features in 26 cases. Respiration. 2005;723:254-262Reference #3: Sveinsson OA, Isaksson HJ, Sigvaldason A, Yngvason F, Aspelund T, Gudmundsson G. Clinical features in secondary and cryptogenic organising pneumonia. Int J Tuberc Lung Dis. 2009DISCLOSURE: The following authors have nothing to disclose: Gilmar Zonzin, Christian Boechat, Gabriela de Souza, Silvio Guerra, Priscila das Virgens, Jamile Abdalla, Vinícius AgostinhoNo Product/Research Disclosure Information.